Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free GCTK Stock Alerts

GlucoTrack (GCTK) Financials

GlucoTrack logo
$3.53 -0.15 (-4.08%)
Closing price 04:00 PM Eastern
Extended Trading
$3.66 +0.13 (+3.54%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for GlucoTrack

Annual Income Statements for GlucoTrack

This table shows GlucoTrack's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.84 -5.41 -10 -6.72 -3.52 -2.70 -4.07 -4.44 -7.10 -23 -19
Consolidated Net Income / (Loss)		 -5.84 -5.41 -10 -6.72 -3.52 -2.70 -4.07 -4.44 -7.10 -23 -19
Net Income / (Loss) Continuing Operations		 -5.84 -5.41 -10 -6.72 -3.52 -2.79 -4.07 -4.44 -7.10 -23 -19
Total Pre-Tax Income 		-5.84 -5.41 -10 -6.72 -3.52 -2.79 -4.07 -4.44 -7.10 -23 -19
Total Operating Income		 -4.66 -5.66 -11 -6.54 -3.51 -3.13 -4.04 -4.43 -7.10 -15 -16
Total Gross Profit		 0.14 0.61 0.59 0.04 0.21 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.14 0.61 0.59 0.04 0.21 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.80 6.27 11 6.58 3.71 3.13 4.04 4.43 7.10 15 16
Selling, General & Admin Expense		 2.53 3.39 6.43 2.46 1.54 1.19 2.09 2.47 2.28 5.05 6.28
Research & Development Expense		 2.27 2.88 3.21 3.03 1.61 1.53 1.81 1.97 4.70 9.50 9.81
Total Other Income / (Expense), net		 -1.19 0.25 0.25 -0.18 -0.01 0.34 -0.03 -0.00 0.00 -8.05 -3.30
Other Income / (Expense), net		 -1.19 0.25 0.25 -0.18 -0.01 0.34 -0.05 -0.01 0.00 -8.05 -3.30
Basic Earnings per Share		 ($1.15) ($1.08) ($1.87) ($4.74) ($0.02) - $0.26 $0.29 $34.18 $4,106.00 $31.22
Weighted Average Basic Shares Outstanding		 5.48M 5.79M 6.29M 8.40M 154.93M 15.08B 15.45M 15.47M 207.60K 5.50K 621.09K
Diluted Earnings per Share		 ($1.15) ($1.08) ($1.87) ($4.74) ($0.02) $0.19 - $0.29 $34.18 $4,106.00 $31.22
Weighted Average Diluted Shares Outstanding		 5.48M 5.79M 6.29M 8.40M 154.93M 15.08B 15.45B 15.47M 207.60K 5.50K 621.09K
Weighted Average Basic & Diluted Shares Outstanding		 5.32M 6.05M 7.26M 8.40M 154.93M 15.08B 15.45B 15.50M 26.76M 25.59M 1.94M

Quarterly Income Statements for GlucoTrack

This table shows GlucoTrack's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.41 -2.93 -4.49 -5.09 -10 -6.83 -4.76 -4.17 -3.63 -4.33 -3.81
Consolidated Net Income / (Loss)		 -2.41 -2.93 -4.49 -5.09 -10 -6.83 -4.76 -4.17 -3.63 -4.33 -3.81
Net Income / (Loss) Continuing Operations		 -2.42 -2.95 -4.49 -5.09 -10 -6.83 -4.76 -4.17 -3.63 -4.33 -3.81
Total Pre-Tax Income 		-2.42 -2.95 -4.49 -5.09 -10 -6.83 -4.76 -4.17 -3.63 -4.33 -3.81
Total Operating Income		 -2.42 -2.95 -4.49 -3.25 -3.85 -3.50 -4.80 -4.31 -3.49 -4.20 -3.40
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Other Revenue		 - 0.00 - - - - - - - - 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 2.42 2.95 4.49 3.25 3.85 3.50 4.80 4.31 3.49 4.20 3.40
Selling, General & Admin Expense		 0.55 0.73 0.80 1.06 2.45 1.63 1.65 1.02 2.29 2.07 1.38
Research & Development Expense		 1.74 2.15 3.59 2.06 1.70 1.87 3.15 3.17 1.63 2.13 2.02
Total Other Income / (Expense), net		 -0.00 0.00 0.00 -1.84 -6.22 -3.34 0.04 0.14 -0.14 -0.13 -0.41
Other Income / (Expense), net		 -0.00 0.00 0.00 0.01 -8.06 -3.34 0.01 0.14 -0.11 -0.13 -0.41
Basic Earnings per Share		 ($11.62) ($11.73) $984.00 $1,092.00 ($1,834.27) $40.14 $9.62 $4.64 ($5.84) $2.65 $0.76
Weighted Average Basic Shares Outstanding		 207.60K 249.60K 4.56K 4.66K 5.50K 169.35K 494.50K 899.41K 621.09K 1.64M 5.01M
Diluted Earnings per Share		 ($11.62) ($11.73) $984.00 $1,092.00 ($1,834.27) $40.14 $9.62 $4.64 ($5.84) $2.65 $0.76
Weighted Average Diluted Shares Outstanding		 207.60K 249.60K 4.56K 4.66K 5.50K 169.35K 494.50K 899.41K 621.09K 1.64M 5.01M
Weighted Average Basic & Diluted Shares Outstanding		 26.76M 27.39M 5.48M 5.77M 25.59M 28.64M 899.41K 910.69K 1.94M 6.26M 10.58M

Annual Cash Flow Statements for GlucoTrack

This table details how cash moves in and out of GlucoTrack's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -5.22 -0.46 21 0.06 7.31 9.41 -3.77 -3.78 2.17 1.13 1.76
Net Cash From Operating Activities		 -4.57 -5.31 -5.90 -4.89 -3.90 -3.50 -3.77 -3.73 -6.56 -12 -15
Net Cash From Continuing Operating Activities		 -4.57 -5.31 15 -4.89 3.13 -3.50 -3.77 -3.73 -6.56 -12 -15
Net Income / (Loss) Continuing Operations		 -5.84 -5.41 10 -6.72 3.52 -2.70 -4.07 -4.44 -7.10 -23 -19
Consolidated Net Income / (Loss)		 -5.84 -5.41 -10 -6.72 -3.52 -2.70 -4.07 -4.44 -7.10 -23 -19
Depreciation Expense		 0.04 0.06 0.07 0.06 0.05 0.05 0.04 0.02 0.01 0.04 0.04
Amortization Expense		 - - - - - - - - 0.00 0.63 0.18
Non-Cash Adjustments To Reconcile Net Income		 1.15 -0.01 2.41 0.70 0.52 0.18 0.31 0.50 0.34 9.38 3.72
Changes in Operating Assets and Liabilities, net		 0.08 0.05 1.96 1.06 -0.95 -1.03 -0.05 0.18 0.19 0.07 0.21
Net Cash From Investing Activities		 -0.20 -0.08 -0.02 -0.01 -0.02 -0.05 -0.00 0.00 0.00 -0.10 -0.10
Net Cash From Continuing Investing Activities		 -0.20 -0.08 -0.02 -0.01 -0.02 -0.05 -0.00 0.00 0.00 -0.10 -0.10
Purchase of Property, Plant & Equipment		 -0.14 -0.08 -0.02 -0.01 -0.02 -0.05 -0.01 -0.00 0.00 -0.10 -0.10
Net Cash From Financing Activities		 -0.46 4.94 5.75 4.96 4.20 13 0.00 0.00 8.73 14 17
Net Cash From Continuing Financing Activities		 -0.46 4.94 5.75 4.96 4.20 13 0.00 0.00 8.73 14 17
Repurchase of Common Equity		 - - - - - - - - - 0.00 -0.17
Issuance of Debt		 0.00 1.64 1.78 - - - - - 0.00 4.36 3.00
Issuance of Common Equity		 0.00 0.00 0.38 4.96 4.20 13 - - 0.00 0.10 3.54
Other Financing Activities, net		 0.04 0.00 - - - - - 0.00 8.73 9.28 11
Effect of Exchange Rate Changes		 0.01 -0.01 0.07 - - -0.05 -0.00 -0.05 -0.00 -0.02 0.05
Cash Interest Paid		 - - - - - - - - 0.00 0.06 0.05

Quarterly Cash Flow Statements for GlucoTrack

This table details how cash moves in and out of GlucoTrack's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -2.40 -3.00 -1.34 0.19 5.27 3.48 0.45 -1.69 -0.49 -3.45 -2.81
Net Cash From Operating Activities		 -2.41 -2.94 -1.91 -4.14 -3.50 -2.94 -3.74 -4.62 -3.94 -4.05 -3.62
Net Cash From Continuing Operating Activities		 -2.41 -2.94 -1.91 -4.14 -3.50 -2.94 -3.74 -4.62 -3.94 -4.05 -3.62
Net Income / (Loss) Continuing Operations		 -2.41 -2.93 -4.49 -5.09 -10 -6.83 -4.76 -4.17 -3.63 -4.33 -3.81
Consolidated Net Income / (Loss)		 -2.41 -2.93 -4.49 -5.09 -10 -6.83 -4.76 -4.17 -3.63 -4.33 -3.81
Depreciation Expense		 -0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02
Amortization Expense		 - 0.00 - 0.33 0.30 0.00 0.00 0.03 0.15 0.15 0.15
Non-Cash Adjustments To Reconcile Net Income		 0.07 0.10 0.25 1.57 7.45 3.42 0.03 0.05 0.23 0.06 0.33
Changes in Operating Assets and Liabilities, net		 -0.06 -0.12 2.32 -0.97 -1.17 0.47 0.97 -0.54 -0.69 0.06 -0.30
Net Cash From Financing Activities		 - 0.00 0.58 4.38 8.78 6.40 4.16 2.99 3.49 0.59 0.80
Net Cash From Continuing Financing Activities		 - 0.00 0.58 4.38 8.78 6.40 4.16 2.99 3.49 0.59 0.80
Other Financing Activities, net		 - 0.00 - - 9.28 6.40 4.32 - -0.05 0.59 1.10
Effect of Exchange Rate Changes		 0.02 0.01 - -0.02 -0.01 0.04 0.03 0.01 -0.02 0.00 0.01
Cash Interest Paid		 - 0.03 0.00 0.01 0.03 0.03 0.05 0.04 -0.07 0.00 0.02

Annual Balance Sheets for GlucoTrack

This table presents GlucoTrack's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 6.35 2.13 2.46 1.67 0.69 11 6.27 2.44 4.91 5.93 7.84
Total Current Assets		 6.05 1.71 2.02 1.23 0.31 10 6.11 2.38 4.87 5.77 7.67
Cash & Equivalents		 5.83 0.61 0.15 0.05 0.10 9.82 6.06 2.31 4.49 5.62 7.38
Other Current Assets		 0.11 0.27 0.36 0.09 0.02 0.06 0.04 0.07 0.38 0.15 0.28
Plant, Property, & Equipment, net		 0.12 0.22 0.24 0.22 0.15 0.15 0.07 0.04 0.03 0.10 0.14
Total Noncurrent Assets		 0.18 0.20 0.20 0.23 0.22 0.23 0.09 0.02 0.01 0.07 0.03
Other Noncurrent Operating Assets		 0.18 0.16 0.17 0.19 0.17 0.23 0.09 0.02 0.01 0.07 0.03
Total Liabilities & Shareholders' Equity		 6.35 2.13 2.46 1.67 0.69 11 6.27 2.44 4.91 5.93 7.84
Total Liabilities		 3.43 2.17 3.37 4.82 3.56 1.62 1.11 1.21 1.71 19 5.01
Total Current Liabilities		 1.00 1.51 2.35 3.69 3.22 1.35 0.88 1.01 1.51 1.28 4.77
Short-Term Debt		 - - - - - - - - 0.00 0.01 3.18
Accounts Payable		 0.10 1.08 1.63 2.42 2.06 0.87 0.63 0.67 0.84 0.99 1.32
Other Current Liabilities		 0.90 0.43 0.71 1.27 1.16 0.48 0.25 0.34 0.67 0.28 0.27
Total Noncurrent Liabilities		 2.43 0.66 1.02 1.14 0.34 0.28 0.23 0.20 0.20 18 0.24
Long-Term Debt		 - - - - - - - - - - 0.23
Other Noncurrent Operating Liabilities		 2.22 0.48 0.84 0.95 0.17 0.28 0.23 0.20 0.20 18 0.01
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -4.83 -6.97 -11 -17 -2.87 8.98 5.16 1.23 3.20 -13 2.83
Total Preferred & Common Equity		 -4.83 -6.97 -11 -17 -2.87 8.98 5.16 1.23 3.20 -13 2.83
Total Common Equity		 -4.83 -6.97 -11 -17 -2.87 8.98 5.16 1.23 3.20 -13 2.83
Common Stock		 18 22 25 31 84 102 103 103 113 119 151
Retained Earnings		 -23 -29 -36 -47 -87 -93 -97 -102 -110 -132 -152
Accumulated Other Comprehensive Income / (Loss)		 0.07 0.09 0.06 0.11 0.16 0.02 -0.01 0.02 0.02 -0.01 0.04
Other Equity Adjustments		 - - - - - - 0.00 0.00 0.05 0.23 3.54

Quarterly Balance Sheets for GlucoTrack

This table presents GlucoTrack's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 7.20 2.11 0.61 0.83 9.61 10 8.29 4.36 1.50
Total Current Assets		 7.17 1.94 0.44 0.64 9.46 10 8.11 4.21 1.38
Cash & Equivalents		 6.89 1.50 0.16 0.35 9.10 9.56 7.87 3.93 1.12
Other Current Assets		 0.28 0.44 0.28 0.30 0.36 0.52 0.24 0.29 0.26
Plant, Property, & Equipment, net		 0.02 0.08 0.09 0.11 0.09 0.09 0.14 0.12 0.10
Total Noncurrent Assets		 0.01 0.09 0.08 0.08 0.06 0.05 0.04 0.03 0.02
Other Noncurrent Operating Assets		 0.01 0.09 0.08 0.08 0.06 0.05 0.04 0.03 0.02
Total Liabilities & Shareholders' Equity		 7.20 2.11 0.61 0.83 9.61 10 8.29 4.36 1.50
Total Liabilities		 1.64 1.73 3.90 4.85 2.35 3.33 5.54 5.21 3.24
Total Current Liabilities		 1.45 1.48 3.66 4.61 1.95 3.09 5.30 4.98 2.99
Short-Term Debt		 - - 0.01 0.01 0.01 0.00 3.03 3.33 1.69
Accounts Payable		 1.25 1.01 2.74 1.86 1.61 2.64 1.71 1.30 1.12
Other Current Liabilities		 0.21 0.47 0.91 2.75 0.33 0.44 0.56 0.35 0.18
Total Noncurrent Liabilities		 0.18 0.25 0.24 0.24 0.40 0.25 0.24 0.23 0.25
Long-Term Debt		 - - - - 0.20 0.22 0.23 0.23 0.25
Other Noncurrent Operating Liabilities		 0.18 0.25 0.24 0.24 0.20 0.02 0.02 0.00 0.00
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.56 0.38 -3.29 -4.02 7.26 6.88 2.75 -0.85 -1.74
Total Preferred & Common Equity		 5.56 0.38 -3.29 -4.02 7.26 6.88 2.75 -0.85 -1.74
Total Common Equity		 5.56 0.38 -3.29 -4.02 7.26 6.88 2.75 -0.85 -1.74
Common Stock		 113 113 114 118 146 151 151 155 158
Retained Earnings		 -107 -113 -117 -122 -139 -144 -148 -156 -160
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.02 0.02 0.01 0.03 0.04 0.04 0.04 0.05
Other Equity Adjustments		 0.00 0.08 0.05 0.10 0.23 0.23 0.23 0.00 0.00

Annual Metrics And Ratios for GlucoTrack

This table displays calculated financial ratios and metrics derived from GlucoTrack's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 5,549,452.00 5,912,702.00 6,521,993.00 8,864,612.00 162,063,299.00 200,669,064.00 15,447,520.00 15,476,665.00 20,892,193.00 5,772,026.00 910,688.00
DEI Adjusted Shares Outstanding		 925.00 985.00 1,087.00 1,477.00 27,011.00 33,445.00 2,575.00 2,579.00 3,482.00 4,810.00 910,688.00
DEI Earnings Per Adjusted Shares Outstanding		 -6,315.86 -5,492.12 -9,502.12 -4,546.66 -130.17 -80.61 -1,579.42 -1,719.66 -2,038.20 -4,697.92 -21.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 139.51% 327.26% -3.63% -92.62% 378.29% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -292.27% 7.71% -91.79% 35.13% 47.95% 20.72% -47.47% -9.18% -60.32% -209.31% 12.62%
EBIT Growth		 -296.02% 7.40% -90.93% 34.98% 47.64% 20.53% -46.49% -8.62% -59.78% -218.09% 14.20%
NOPAT Growth		 9.66% -21.49% -86.99% 38.17% 46.38% 10.67% -28.99% -9.70% -60.29% -104.77% -10.61%
Net Income Growth		 -296.02% 7.40% -90.93% 34.98% 47.64% 23.32% -50.85% -9.05% -60.02% -218.40% 14.20%
EPS Growth		 -410.81% 6.09% -73.15% -153.48% 99.58% 1,050.00% 0.00% 0.00% -60.02% -218.40% -99.24%
Operating Cash Flow Growth		 -35.80% -16.35% -10.98% 17.01% 20.30% 10.21% -7.66% 1.06% -75.86% -90.45% -22.02%
Free Cash Flow Firm Growth		 43.86% 35.46% -48.08% 8.53% 25.24% 9.75% 14.74% -5.99% -62.59% 249.88% -502.76%
Invested Capital Growth		 76.72% -61.19% -197.21% 6.90% 37.55% 55.46% -7.85% -19.29% -19.69% -1,337.22% 93.86%
Revenue Q/Q Growth		 -18.49% 26.86% 130.81% -91.42% 48.30% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -15.16% 8.26% -12.14% -54.41% 56.85% 2.33% -20.24% 4.28% -19.20% -71.94% 28.35%
EBIT Q/Q Growth		 -15.18% 8.14% -12.05% -53.06% 56.43% 2.31% -19.89% 4.37% -18.92% -72.50% 28.52%
NOPAT Q/Q Growth		 -13.34% 3.96% -14.73% -49.03% 54.65% -9.50% -18.34% 4.67% -18.92% -10.96% 2.23%
Net Income Q/Q Growth		 -15.18% 6.98% -17.22% -54.59% 55.75% 4.76% -34.45% 4.71% -18.84% -51.51% 25.01%
EPS Q/Q Growth		 -21.05% 4.42% -175.00% -173.99% 99.55% 416.67% 0.00% 196.67% -18.84% -51.51% 208.59%
Operating Cash Flow Q/Q Growth		 -12.75% 8.48% 2.92% -6.57% 7.00% -1.38% -3.54% 0.88% -28.92% -9.54% -2.95%
Free Cash Flow Firm Q/Q Growth		 -10.90% 8.24% 3.35% -235.81% 47.48% 4.27% -4.19% -2.10% -27.38% 216.10% -104.90%
Invested Capital Q/Q Growth		 -5.65% -21.22% -68.85% 15.19% 11.85% -10.65% -81.76% -22.12% 2.70% -326.59% 38.60%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -4,049.31% -874.65% -1,740.73% -15,306.82% -1,665.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -3,251.69% -924.63% -1,794.15% -15,035.41% -1,685.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -4,080.67% -884.39% -1,752.24% -15,442.01% -1,690.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -4,080.67% -884.39% -1,752.24% -15,442.01% -1,690.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 96.49% 100.00% 100.00% 99.90% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.36% 99.75% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -405.35% 1,148.70% 508.61% 222.85% 244.74% -60.03% -57.54% -138.92% -320.62% 461.02% 381.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -137.77% -235.53% -500.20% -569.80% -394.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -137.77% -235.53% -500.20% -569.80% -394.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 1,659.75% 21,855.25% 3,446.75% 719.11% 244.74% -60.03% -57.54% -138.92% -320.62% 461.02% 381.20%
Return on Equity Simple (ROE_SIMPLE)		 83.81% 49.41% 62.32% 233.72% 0.00% -30.02% -78.89% -360.57% -221.99% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.26 -3.96 -7.40 -4.58 -2.45 -2.19 -2.83 -3.10 -4.97 -10 -11
NOPAT Margin		 -2,276.19% -647.24% -1,255.91% -10,524.79% -1,179.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -79.84% -350.24% -2,105.94% -1,759.80% -104.22% -8.60% -15.60% -31.83% -62.44% -245.73% -169.59%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -155.55% 78.36% -180.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,767.29% 553.50% 1,091.28% 5,649.29% 737.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 1,584.40% 471.12% 544.13% 6,974.02% 772.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 3,351.69% 1,024.63% 1,894.15% 15,135.41% 1,785.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.84 -5.41 -10 -6.72 -3.52 -2.79 -4.09 -4.45 -7.10 -23 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.80 -5.35 -10 -6.66 -3.47 -2.75 -4.05 -4.42 -7.09 -22 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 8.94 12.50 17.74 1.71 0.00 1.25
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 8.94 12.50 17.74 1.71 0.00 1.25
Price to Revenue (P/Rev)		 271.33 67.66 77.45 103.96 467.41 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 315.29 83.78 100.06 100.52 465.40 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.21
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08
Financial Leverage		 -2.25 0.88 0.07 0.04 0.71 -1.30 -1.12 -1.31 -1.54 1.03 0.94
Leverage Ratio		 2.94 -4.88 -1.02 -0.39 -0.62 1.30 1.19 1.36 1.66 -1.11 -1.35
Compound Leverage Factor		 2.94 -4.88 -1.02 -0.39 -0.62 1.30 1.19 1.36 1.66 -1.11 -1.35
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.04% 54.69%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.04% 50.99%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.70%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -20,452.26% -1,105.93% -425.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 20,552.26% 1,205.93% 525.59% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.04% 45.31%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.18
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.26 0.21
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.30
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.55 0.35
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Altman Z-Score		 -17.39 -20.05 -55.89 -213.81 -104.70 17.46 11.88 -53.02 -33.39 -42.85 -34.42
Noncontrolling Interest Sharing Ratio		 509.47% -1,802.60% -577.68% -222.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.13 0.86 0.33 0.10 0.32 7.61 6.91 2.35 3.22 4.52 1.61
Quick Ratio		 0.42 0.10 0.05 0.04 0.22 7.35 6.87 2.28 2.97 4.41 1.55
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.49 -3.54 -5.25 -4.80 -3.59 -3.24 -2.76 -2.93 -4.76 7.13 -29
Operating Cash Flow to CapEx		 -3,176.12% -6,947.66% -30,282.09% -91,086.89% -16,952.17% -6,605.66% -376,900.00% 0.00% 0.00% -12,009.62% -15,875.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.27 0.29 0.04 0.23 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 6.87 11.07 5.51 0.60 4.48 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.83 2.65 2.58 0.24 1.47 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 53.15 32.97 66.21 606.66 81.40 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 53.15 32.97 66.21 606.66 81.40 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.68 -1.09 -3.25 -3.02 -1.89 -0.84 -0.91 -1.08 -1.30 -19 -1.14
Invested Capital Turnover		 -0.08 -0.69 -0.27 -0.01 -0.08 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.23 -0.41 -2.15 0.22 1.13 1.05 -0.07 -0.18 -0.21 -17 17
Enterprise Value (EV)		 45 51 59 4.37 97 70 58 20 0.97 -3.46 -0.45
Market Capitalization		 39 41 46 4.52 97 80 64 22 5.46 2.15 3.52
Book Value per Share		 ($1.26) ($1.85) ($2.54) ($0.32) $0.00 $0.04 $0.33 $0.08 $0.15 ($2.25) $3.11
Tangible Book Value per Share		 ($1.26) ($1.85) ($2.54) ($0.32) $0.00 $0.04 $0.33 $0.08 $0.15 ($2.25) $3.11
Total Capital		 -0.03 -0.91 -3.15 -2.87 0.00 8.98 5.16 1.23 3.20 -13 6.24
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 3.41
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23
Net Debt		 -0.64 -0.18 -0.09 -0.15 -0.42 -9.82 -6.06 -2.31 -4.49 -5.61 -3.97
Capital Expenditures (CapEx)		 0.14 0.08 0.02 0.01 0.02 0.05 0.00 -0.00 0.00 0.10 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.41 -0.48 -2.51 -3.00 -1.97 -0.94 -0.84 -0.95 -1.14 -1.12 -1.31
Debt-free Net Working Capital (DFNWC)		 0.20 -0.33 -2.46 -2.91 -1.55 8.88 5.22 1.37 3.36 4.50 6.08
Net Working Capital (NWC)		 0.20 -0.33 -2.46 -2.91 -1.55 8.88 5.22 1.37 3.36 4.49 2.89
Net Nonoperating Expense (NNE)		 2.58 1.45 2.93 2.14 1.06 0.50 1.24 1.33 2.12 12 8.13
Net Nonoperating Obligations (NNO)		 -0.64 -0.18 -0.09 -0.15 -1.89 -9.82 -6.06 -2.31 -4.49 -5.61 -3.97
Total Depreciation and Amortization (D&A)		 0.04 0.06 0.07 0.06 0.05 0.05 0.04 0.02 0.01 0.66 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 -284.26% -78.39% -426.27% -6,908.90% -948.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 140.91% -54.06% -417.14% -6,685.67% -747.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 140.91% -54.06% -417.14% -6,685.67% -747.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.75) ($5.40) ($9.35) ($23.70) ($0.10) ($0.10) $0.00 $1.45 $38.00 $4,106.40 $31.22
Adjusted Weighted Average Basic Shares Outstanding		 1.10M 1.16M 1.26M 1.68M 30.99M 3.02B 3.09M 3.09M 207.60K 5.50K 621.09K
Adjusted Diluted Earnings per Share		 ($5.75) ($5.40) ($9.35) ($23.70) ($0.10) ($0.10) $1.30 $0.00 $38.00 $4,106.40 $31.22
Adjusted Weighted Average Diluted Shares Outstanding		 1.10M 1.16M 1.26M 1.68M 30.99M 3.02B 3.09M 3.10M 207.60K 5.50K 621.09K
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($5.40) ($9.35) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.06M 1.21M 1.45M 1.68M 30.99M 39.21M 3.09B 3.10M 267.56K 426.43K 1.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.26 -3.96 -7.40 -4.58 -2.45 -2.19 -2.83 -3.10 -4.97 -10 -11
Normalized NOPAT Margin		 -2,276.19% -647.24% -1,255.91% -10,524.79% -1,179.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -4,080.67% -884.39% -1,752.24% -15,442.01% -1,690.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -0.98% -0.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.98% -0.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.86%

Quarterly Metrics And Ratios for GlucoTrack

This table displays calculated financial ratios and metrics derived from GlucoTrack's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 20,892,193.00 26,756,369.00 27,393,002.00 5,478,436.00 5,772,026.00 25,585,853.00 28,642,809.00 899,410.00 910,688.00 1,944,279.00 6,259,279.00
DEI Adjusted Shares Outstanding		 3,482.00 4,459.00 4,566.00 4,565.00 4,810.00 426,431.00 477,380.00 899,410.00 910,688.00 1,944,279.00 6,259,279.00
DEI Earnings Per Adjusted Shares Outstanding		 -692.71 -656.43 -983.14 -1,114.35 -2,098.54 -16.02 -9.96 -4.64 -3.98 -2.23 -0.61
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -89.17% -129.88% -282.18% -31.24% -378.12% -131.49% -6.45% -42.57% 70.38% 38.96% 23.66%
EBIT Growth		 -87.96% -129.47% -281.89% -45.70% -392.60% -131.55% -6.55% -28.84% 69.81% 36.57% 20.29%
NOPAT Growth		 -87.80% -129.83% -280.92% -46.18% -59.45% -18.54% -6.79% -32.54% 9.52% -20.15% 29.11%
Net Income Growth		 -87.41% -127.61% -281.72% -128.83% -318.49% -133.45% -5.95% 18.01% 64.06% 36.57% 19.81%
EPS Growth		 -87.41% -127.61% -281.72% -128.83% -318.49% -133.45% -99.02% -99.58% 99.68% -93.40% -92.10%
Operating Cash Flow Growth		 -156.49% -124.07% -99.90% -120.32% -45.13% 0.10% -96.33% -11.56% -12.49% -37.73% 3.42%
Free Cash Flow Firm Growth		 -103.73% -316.67% -61.18% 168.02% 1,088.52% -0.05% -487.41% -829.78% -236.20% -73.21% 9.91%
Invested Capital Growth		 -19.69% -13.00% -233.27% -227.80% -1,337.22% -45.58% 28.58% 57.37% 93.86% 25.37% 62.31%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.87% -21.43% -52.12% 35.33% -300.28% 41.21% 30.05% 13.39% 16.84% -21.15% 12.51%
EBIT Q/Q Growth		 -8.82% -21.99% -52.19% 27.88% -267.89% 42.66% 29.97% 12.79% 13.80% -20.49% 12.00%
NOPAT Q/Q Growth		 -8.68% -22.09% -52.19% 27.61% -18.55% 9.24% -37.11% 10.15% 19.08% -20.53% 19.11%
Net Income Q/Q Growth		 -8.50% -21.35% -53.37% -13.32% -98.43% 32.31% 30.40% 12.30% 13.02% -19.46% 12.00%
EPS Q/Q Growth		 -8.50% -21.35% -53.37% -13.32% -98.43% 32.31% -76.03% -51.77% -225.86% 145.38% -71.32%
Operating Cash Flow Q/Q Growth		 -28.24% -22.02% 35.18% -117.20% 15.52% 16.00% -27.39% -23.42% 14.82% -2.85% 10.67%
Free Cash Flow Firm Q/Q Growth		 -33.02% -30.96% 61.86% 202.38% 1,832.99% -113.25% -123.95% -27.20% -260.75% 83.14% -16.47%
Invested Capital Q/Q Growth		 2.70% 13.44% -206.51% -26.98% -326.59% 91.23% -50.37% 24.21% 38.60% -6.66% 24.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.71% 99.19% 100.00% 100.00% 100.24% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 99.96% 157.05% 84.51% 100.00% 99.39% 99.95% 100.86% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -320.62% -4,574.87% -541.13% -1,943.32% 461.02% -694.34% -1,490.95% 4,068.29% 381.20% -527.20% -620.63%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -320.62% -4,574.87% -541.74% -1,943.32% 461.02% -694.34% -1,490.95% 4,068.29% 381.20% -527.20% -620.63%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -2,323.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.69 -2.07 -3.14 -2.28 -2.70 -2.45 -3.36 -3.02 -2.44 -2.94 -2.38
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -21.17% -69.04% -30.16% -77.78% -146.40% -84.42% -29.51% -46.64% -24.78% -30.07% -33.67%
Return On Investment Capital (ROIC_SIMPLE)		 -52.92% -549.39% 95.93% 56.65% 20.76% -32.79% -47.28% -50.20% -39.11% -108.52% -1,195.98%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.42 -2.95 -4.49 -3.24 -12 -6.83 -4.79 -4.17 -3.60 -4.33 -3.81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.43 -2.95 -4.48 -2.90 -12 -6.82 -4.77 -4.13 -3.44 -4.16 -3.64
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.71 23.56 0.00 0.00 0.00 0.62 0.42 2.15 1.25 0.00 0.00
Price to Tangible Book Value (P/TBV)		 1.71 23.56 0.00 0.00 0.00 0.62 0.42 2.15 1.25 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.03 0.03 1.18 1.21 -4.19 -1.11
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.08 0.08 -0.27 -0.14
Financial Leverage		 -1.54 -6.53 -2.00 -4.71 1.03 -1.36 -2.64 3.90 0.94 -1.44 -1.66
Leverage Ratio		 1.66 8.79 2.15 5.23 -1.11 1.54 3.01 -7.17 -1.35 2.18 2.28
Compound Leverage Factor		 1.66 8.79 2.15 8.21 -0.93 1.54 2.99 -7.17 -1.37 2.18 2.28
Debt to Total Capital		 0.00% 0.00% -0.37% -0.12% -0.04% 2.81% 3.11% 54.22% 54.69% 131.39% 974.87%
Short-Term Debt to Total Capital		 0.00% 0.00% -0.37% -0.12% -0.04% 0.12% 0.00% 50.44% 50.99% 122.83% 850.25%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 2.69% 3.11% 3.78% 3.70% 8.56% 124.62%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.37% 100.12% 100.04% 97.19% 96.89% 45.78% 45.31% -31.39% -874.87%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.12 -0.18 -0.22 -0.13
Net Debt to EBITDA		 0.00 0.00 0.01 0.03 0.26 0.34 0.36 0.17 0.21 0.02 -0.05
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.02
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.28 -0.30 -0.30 -0.18
Net Debt to NOPAT		 0.00 0.00 0.02 0.04 0.55 0.84 0.87 0.40 0.35 0.03 -0.08
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02
Altman Z-Score		 -30.24 -76.26 -299.06 -224.46 -36.91 -20.56 -19.96 -25.64 -27.77 -53.54 -159.16
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% -0.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.22 1.31 0.12 0.14 4.52 4.85 3.27 1.53 1.61 0.85 0.46
Quick Ratio		 2.97 1.01 0.04 0.08 4.41 4.67 3.10 1.49 1.55 0.79 0.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.48 -1.94 -0.74 0.76 15 -1.94 -4.34 -5.52 -20 -3.36 -3.91
Operating Cash Flow to CapEx		 0.00% -4,986.44% -15,891.67% -12,551.52% 0.00% -32,655.56% 0.00% -6,897.01% -19,680.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.30 -1.12 -3.44 -4.36 -19 -1.63 -2.45 -1.86 -1.14 -1.22 -0.93
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.21 -0.13 -2.41 -3.03 -17 -0.51 0.98 2.50 17 0.41 1.53
Enterprise Value (EV)		 0.97 7.36 11 13 -3.46 -4.43 -6.47 1.32 -0.45 0.90 2.81
Market Capitalization		 5.46 8.86 11 13 2.15 4.46 2.86 5.93 3.52 1.26 2.00
Book Value per Share		 $0.15 $0.01 ($0.12) ($0.73) ($2.25) $1.26 $0.24 $3.06 $3.11 ($0.44) ($0.28)
Tangible Book Value per Share		 $0.15 $0.01 ($0.12) ($0.73) ($2.25) $1.26 $0.24 $3.06 $3.11 ($0.44) ($0.28)
Total Capital		 3.20 0.38 -3.28 -4.02 -13 7.47 7.10 6.01 6.24 2.71 0.20
Total Debt		 0.00 0.00 0.01 0.01 0.01 0.21 0.22 3.26 3.41 3.56 1.94
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.20 0.22 0.23 0.23 0.23 0.25
Net Debt		 -4.49 -1.50 -0.15 -0.34 -5.61 -8.89 -9.33 -4.61 -3.97 -0.37 0.82
Capital Expenditures (CapEx)		 0.00 0.06 0.01 0.03 0.00 0.01 0.00 0.07 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.14 -1.04 -3.37 -4.31 -1.12 -1.59 -2.56 -2.03 -1.31 -1.36 -1.04
Debt-free Net Working Capital (DFNWC)		 3.36 0.46 -3.21 -3.96 4.50 7.51 6.99 5.84 6.08 2.57 0.09
Net Working Capital (NWC)		 3.36 0.46 -3.22 -3.97 4.49 7.51 6.99 2.81 2.89 -0.76 -1.61
Net Nonoperating Expense (NNE)		 0.72 0.86 1.35 2.81 7.40 4.38 1.40 1.15 1.19 1.39 1.43
Net Nonoperating Obligations (NNO)		 -4.49 -1.50 -0.15 -0.34 -5.61 -8.89 -9.33 -4.61 -3.97 -0.37 0.82
Total Depreciation and Amortization (D&A)		 -0.01 0.00 0.01 0.34 0.31 0.01 0.01 0.04 0.16 0.17 0.17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1,162.00) ($12.00) $984.00 ($1,092.00) ($2,201,124.00) ($40.20) $9.62 $4.64 ($5.84) $2.65 $0.76
Adjusted Weighted Average Basic Shares Outstanding		 2.08K 249.60K 4.56K 4.66K 5.00 169.35K 494.50K 899.41K 621.09K 1.64M 5.01M
Adjusted Diluted Earnings per Share		 ($1,162.00) ($12.00) $984.00 ($1,092.00) ($2,201,124.00) ($40.20) $9.62 $4.64 ($5.84) $2.65 $0.76
Adjusted Weighted Average Diluted Shares Outstanding		 2.08K 249.60K 4.56K 4.66K 5.00 169.35K 494.50K 899.41K 621.09K 1.64M 5.01M
Adjusted Basic & Diluted Earnings per Share		 ($1,162.00) $0.00 $0.00 $0.00 ($2,201,124.00) $0.00 $0.00 $0.00 ($5.84) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 267.56K 273.93K 4.57K 4.81K 21.32K 477.38K 899.41K 910.69K 1.94M 6.26M 10.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.69 -2.07 -3.14 -2.28 -2.70 -2.45 -3.36 -3.02 -2.44 -2.94 -2.38
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.60% 0.00% -0.86% 0.00% -0.04%

Financials Breakdown Chart

Key Financial Trends

GlucoTrack (NASDAQ:GCTK) remains a pre-revenue development-stage company with significant funding needs. The company reported zero revenue in every period provided, from the third quarter of 2023 through the second quarter of 2026. As a result, operating performance continues to be driven almost entirely by research and development and corporate expenses rather than commercial sales.

There was some sequential improvement in the latest quarter. Q2 2026 operating expenses declined to $3.4 million from $4.2 million in Q1 2026 and $4.8 million in Q2 2025. The net loss narrowed to $3.8 million, compared with $4.3 million in Q1 2026 and $4.8 million in Q2 2025. However, the improvement has not yet translated into positive cash flow or revenue growth.

Liquidity remains the central concern. Cash and equivalents fell from $3.9 million at March 31, 2026, to $1.1 million at June 30, 2026. The company used $3.6 million in operating cash during Q2 and reported a $2.8 million quarterly decline in cash despite $803,000 of financing inflows. At the latest operating burn rate, existing cash appears insufficient to fund operations for an extended period without additional financing or substantial expense reductions.

The balance sheet also shows financial stress. Total liabilities of $3.2 million exceeded total assets of $1.5 million, resulting in negative shareholders’ equity of $1.7 million. Although short-term debt declined from $3.3 million in Q1 2026 to $1.7 million in Q2, accounts payable remained elevated at $1.1 million. Investors should also be aware that several historical income statement and share-count figures were restated or calculated, making period-to-period EPS comparisons less reliable.

  • Operating expenses are trending lower: Q2 2026 operating expenses of $3.4 million were down approximately 19% from Q1 2026 and 29% from Q2 2025.
  • The quarterly net loss improved sequentially: The $3.8 million Q2 loss was smaller than the $4.3 million loss in Q1 2026 and the $4.8 million loss in Q2 2025.
  • Short-term debt decreased: Short-term debt fell by roughly $1.6 million from Q1 2026, helping reduce total liabilities from $5.2 million to $3.2 million.
  • Research spending remains substantial: R&D expense was $2.0 million in Q2 2026, or nearly 60% of operating expenses. This may support future product development, but it has not yet produced reported revenue.
  • Share counts have been highly volatile: Weighted average basic shares increased to approximately 5.0 million in Q2 2026 from 1.6 million in Q1 2026, complicating EPS comparisons and highlighting potential dilution or capital-structure changes.
  • Revenue has remained at zero: GlucoTrack reported no revenue in all periods provided, leaving no evidence of an established commercial business or recurring operating cash inflow.
  • Operating cash flow remains deeply negative: Cash used in operations was $3.6 million in Q2 2026, following $4.0 million in Q1 2026 and $3.9 million in Q4 2025.
  • Liquidity is rapidly deteriorating: Cash declined from $9.6 million at June 30, 2025, to $1.1 million one year later, while the latest quarter ended with current liabilities more than twice current assets.
  • The company has negative equity: Shareholders’ equity deteriorated from positive $7.3 million at March 31, 2025, to negative $1.7 million at June 30, 2026.
  • Additional financing appears likely: Financing inflows have repeatedly offset operating losses, including $803,000 in Q2 2026 and $591,000 in Q1 2026. Continued reliance on financing could increase debt obligations or dilute existing shareholders.
09/03/26 12:10 AM ETAI Generated. May Contain Errors.

GlucoTrack Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GlucoTrack's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

GlucoTrack's net income appears to be on an upward trend, with a most recent value of -$19.39 million in 2025, rising from -$5.84 million in 2015. The previous period was -$22.60 million in 2024. View GlucoTrack's forecast to see where analysts expect GlucoTrack to go next.

GlucoTrack's total operating income in 2025 was -$16.09 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $16.09 million

Over the last 10 years, GlucoTrack's total revenue changed from $143.17 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

GlucoTrack's total liabilities were at $5.01 million at the end of 2025, a 73.5% decrease from 2024, and a 46.0% increase since 2014.

In the past 10 years, GlucoTrack's cash and equivalents has ranged from $53.78 thousand in 2017 to $9.82 million in 2020, and is currently $7.38 million as of their latest financial filing in 2025.

Over the last 10 years, GlucoTrack's book value per share changed from -1.26 in 2015 to 3.11 in 2025, a change of -347.2%.


Related Companies

Financial statements for NASDAQ:GCTK last updated on 8/31/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Why Boston Ships In Natural Gas It Already Has at Home
A tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...
Porter & Company | Sponsoredtc pixel
#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"
The federal government is throwing its full support behind a new class of AI technology, in what's being calle...
Stansberry Research | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel